<DOC>
	<DOCNO>NCT02544308</DOCNO>
	<brief_summary>The purpose trial establish whether adjuvant therapy lenalidomide + dexamethasone radiotherapy improve progression free survival patient high risk solitary bone plasmacytoma compare RT .</brief_summary>
	<brief_title>Trial Immunomodulatory Therapy High Risk Solitary Bone Plasmacytoma</brief_title>
	<detailed_description>Solitary bone plasmacytoma ( SBP ) localise proliferation malignant plasma cell ( PCs ) skeleton . The annual UK incidence 0.4/100,000 ( low multiple myeloma ( MM ) ) peak age incidence 68 year estimate 260 new case per year United Kingdom ( UK ) . The majority patient SBP ultimately progress myeloma likely due occult disease detect conventional staging method . Standard care patient involve field radiotherapy ( IFRT ) , despite radical dos , two-thirds develop multiple myeloma median 2 year , high risk feature . The IDRIS Trial phase III study investigator hope demonstrate adjuvant lenalidomide + dexamethasone follow IFRT prevents development multiple myeloma patient high risk solitary bone plasmacytoma . Whilst proportion solitary bone plasmacytoma cure IFRT , clear majority progress multiple myeloma . The investigator seek prevent outcome use adjuvant therapy study .</detailed_description>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients newlydiagnosed SBP define IMWG BCSH guideline 2 . Treated local radiotherapy per BCSH guideline 3 . Radiotherapy complete within 28 day prior registration 4 . Age ≥18 year 5 . Creatinine &lt; 400µmol/L 6 . ECOG performance status 02 7 . Written inform consent 8 . Willing comply requirement Celgene pregnancy prevention programme 1 . Multifocal plasmacytoma , solitary extramedullary plasmacytoma myeloma 2 . ≥10 % bone marrow plasma cell 3 . Clinical suspicion failure respond radiotherapy 4 . On , plan , systemic steroid therapy ( e.g . Dexamethasone ) unless otherwise agree TMG . 5 . Severe hepatic impairment ( bilirubin &gt; 2 x ULN AST/ALT &gt; 2xULN ) 6 . Pregnant lactating woman . 7 . Nonhaematological malignancy within past 3 year exception ( ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; ( b ) carcinoma situ cervix breast ; ( c ) prostate cancer Gleason grade 6 less stable prostatespecific antigen level ; ( ) cancer consider cure surgical resection unlikely impact survival duration study , localise transitional cell carcinoma bladder benign tumours adrenal gland pancreas 8 . Patients high risk venous thromboembolism due : 1 . Treatment erythropoietic stimulating agent ( e.g . erythropoetin , epoetin alpha , neorecormon , aranesp ) 2 . Other risk factor list 9 . Patients untreated osteoporosis 10 . Patients uncontrolled diabetes 11 . Patients glaucoma 12 . Any medical psychiatric condition likely interfere study participation 13 . Receiving treatment experimental drug experimental medical device . Concurrent participation nontreatment study allow , interfere participation study . Any experimental drug treatment must stop within 4 week prior plan start lenalidomide dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solitary , Bone</keyword>
</DOC>